MAPT and Alzheimer disease: To further test whether HDAC6 inhibition results in a reduction of tau pathology, several additional HDAC6-selective inhibitors were examined in the tau inclusion model in which compounds, along with AD-tau, were added to rat cortical neurons cultures at DIV7.